We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
-3.14%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$52.8B
AUM Growth
-$1.34B
(-2.5%)
Cap. Flow
+$1.39B
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
12%
Holding
4,607
New
780
Increased
956
Reduced
789
Closed
1,336
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$532M |
| 2 |
Wells Fargo
WFC
|
+$480M |
| 3 |
Visa
V
|
+$435M |
| 4 |
Verizon
VZ
|
+$320M |
| 5 |
Broadcom
AVGO
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$547M |
| 2 |
Meta Platforms (Facebook)
META
|
+$525M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$498M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$456M |
| 5 |
Amazon
AMZN
|
+$445M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 18.66% |
| 2 | Technology | 16.35% |
| 3 | Healthcare | 16.13% |
| 4 | Consumer Discretionary | 11.2% |
| 5 | Industrials | 7.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3026
TriplePoint Venture Growth BDC
TPVG
$185M
| $230K | ﹤0.01% |
+13,184
| New | +$223K |
|
3027
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.91B
| $230K | ﹤0.01% |
2,457
-2,113
| -46% | -$205K |
|
3028
Walker & Dunlop
WD
$1.75B
| $230K | ﹤0.01% |
+1,783
| New | +$245K |
|
3029
Vitamin Cottage Natural Grocers
NGVC
$744M
| $229K | ﹤0.01% |
11,718
-38,877
| -77% | -$644K |
|
3030
Quad
QUAD
$434M
| $229K | ﹤0.01% |
33,008
-193,096
| -85% | -$1.01M |
|
|
USAP
3031
DELISTED
Universal Stainless & Alloy
USAP
| $229K | ﹤0.01% |
+26,398
| New | +$241K |
|
3032
CALL
Japer Therapeutics Warrants
JSPRW
$182K
| $228K | ﹤0.01% |
64,313
-3,477
| -5% | -$1.94K |
|
|
PDS
3033
Precision Drilling
PDS
$1.01B
| $228K | ﹤0.01% |
3,092
+1,388
| +81% | +$73.6K |
|
3034
PEDEVCO
PED
$148M
| $228K | ﹤0.01% |
8,462
+5,110
| +152% | +$135K |
|
3035
Malibu Boats
MBUU
$559M
| $227K | ﹤0.01% |
3,914
-5,325
| -58% | -$343K |
|
3036
Orion Energy Systems
OESX
$41.8M
| $227K | ﹤0.01% |
8,117
-15,417
| -66% | -$495K |
|
3037
Spero Therapeutics
SPRO
$69.5M
| $227K | ﹤0.01% |
+26,027
| New | +$267K |
|
|
MBTC
3038
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $227K | ﹤0.01% |
22,522
| – | – |
|
3039
Quaker Houghton
KWR
$2.67B
| $224K | ﹤0.01% |
1,295
| – | – |
|
3040
Red Violet
RDVT
$938M
| $224K | ﹤0.01% |
7,880
-1,541
| -16% | -$43.3K |
|
|
THCPW
3041
CALL
DELISTED
Thunder Bridge Capital Partners IV, Inc. Warrant
THCPW
| $224K | ﹤0.01% |
22,526
+2,230
| +11% | +$1.53K |
|
|
SUNW
3042
DELISTED
Sunworks, Inc.
SUNW
| $224K | ﹤0.01% |
89,095
+63,383
| +247% | +$160K |
|
3043
Coinbase
COIN
$44.2B
| $223K | ﹤0.01% |
1,172
-701
| -37% | -$137K |
|
3044
Mitek Systems
MITK
$758M
| $223K | ﹤0.01% |
+15,179
| New | +$232K |
|
|
UROY
3045
Uranium Royalty Corp
UROY
$439M
| $223K | ﹤0.01% |
56,916
-90,286
| -61% | -$343K |
|
3046
Citizens & Northern Corp
CZNC
$450M
| $221K | ﹤0.01% |
9,062
-588
| -6% | -$14.9K |
|
3047
Tango Therapeutics
TNGX
$4.34B
| $220K | ﹤0.01% |
28,915
+22,646
| +361% | +$196K |
|
3048
ESS Tech
GWH
$22.1M
| $219K | ﹤0.01% |
2,618
-4,547
| -63% | -$406K |
|
3049
CI&T Inc
CINT
$422M
| $218K | ﹤0.01% |
13,644
-417,393
| -97% | -$6.11M |
|
|
LGHL
3050
Lion Group Holding
LGHL
$997K
| – | – |
0
| – | – |
|
Similar funds
Marshall Wace's Q1 2022 Portfolio in Review
As of Q1 2022, Marshall Wace held 4,607 positions worth $52.8B, down 2.5% from $54.2B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Marshall Wace's Q1 2022 filing shows 780 new, 956 increased, 789 reduced and 1,336 closed positions. Its largest new stake was Agilent Technologies: 1,082,487 shares worth $143M. The largest sale was Microsoft, an estimated $547M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.
- Marshall Wace's largest Q1 2022 buy was Agilent Technologies: 1,082,487 shares worth $143M.
- Marshall Wace added most to Merck in Q1 2022, an estimated $532M increase.
- Marshall Wace's biggest Q1 2022 reduction was Microsoft, cutting an estimated $547M.
- Marshall Wace fully exited Elevance Health in Q1 2022, selling an estimated $226M.
- Marshall Wace's ten largest holdings make up 12% of its $52.8B portfolio in Q1 2022.
- Marshall Wace opened 780 new positions and closed 1,336 in Q1 2022.
- Marshall Wace's portfolio value fell 2.5% quarter-over-quarter to $52.8B.
Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.